Metagenomic insights into fungal community composition of the nasopharyngeal region of COVID-19 associated mucormycosis patients from India.
COVID‐19
COVID‐associated mucormycosis (CAM)
coronavirus
mycobiome
nasopharyngeal flora
Journal
Journal of medical virology
ISSN: 1096-9071
Titre abrégé: J Med Virol
Pays: United States
ID NLM: 7705876
Informations de publication
Date de publication:
Apr 2024
Apr 2024
Historique:
revised:
22
03
2024
received:
13
02
2024
accepted:
01
04
2024
medline:
10
4
2024
pubmed:
10
4
2024
entrez:
10
4
2024
Statut:
ppublish
Résumé
Coronavirus disease 2019 (COVID-19) associated mucormycosis (CAM) was reported predominantly from India during the second wave of COVID-19 and has a high mortality rate. The present study aims to understand the fungal community composition of the nasopharyngeal region of CAM-infected individuals and compare it with severe COVID-19 patients and healthy controls. The fungal community composition was decoded by analyzing the sequence homology of the internal transcribed spacer-2-(ITS-2) region of metagenomic DNA extracted from the upper respiratory samples. The alpha-diversity indices were found to be significantly altered in CAM patients (p < 0.05). Interestingly, a higher abundance of Candida africana, Candida haemuloni, Starmerella floris, and Starmerella lactiscondensi was observed exclusively in CAM patients. The interindividual changes in mycobiome composition were well supported by beta-diversity analysis (p < 0.05). The current study provides insights into the dysbiosis of the nasal mycobiome during CAM infection. In conclusion, our study shows that severe COVID-19 and CAM are associated with alteration in mycobiome as compared to healthy controls. However, the sequential alteration in the fungal flora which ultimately leads to the development of CAM needs to be addressed by future studies.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e29601Subventions
Organisme : All-India Institute of Medical Sciences Intramural Grant
Organisme : Department of Biotechnology (DBT), Govt. of India
ID : RAD-22017/19/2022-KGD-DBT
Informations de copyright
© 2024 Wiley Periodicals LLC.
Références
Hoenigl M, Seidel D, Carvalho A, et al. The emergence of COVID‐19 associated mucormycosis: a review of cases from 18 countries. Lancet Microbe. 2022;3(7):e543‐e552.
Kumar S, Mehta S, Sarangdhar N, Ray A, Sinha S, Wig N. Management of COVID‐19 from the pulmonologist's perspective: a narrative review. Expert Rev Respir Med. 2021;15(4):519‐535.
Muthu V, Rudramurthy SM, Chakrabarti A, Agarwal R. Epidemiology and pathophysiology of COVID‐19‐associated mucormycosis: India versus the rest of the world. Mycopathologia. 2021;186(6):739‐754.
Blaser MJ. The microbiome revolution. J Clin Invest. 2014;124(10):4162‐4165.
Thaiss CA, Zmora N, Levy M, Elinav E. The microbiome and innate immunity. Nature. 2016;535(7610):65‐74.
Tiew PY, Mac Aogain M, Ali NABM, et al. The mycobiome in health and disease: emerging concepts, methodologies and challenges. Mycopathologia. 2020;185(2):207‐231.
Cui L, Morris A, Ghedin E. The human mycobiome in health and disease. Genome Med. 2013;5(7):63.
Sellart‐Altisent M, Torres‐Rodríguez JM, Gómez de Ana S, Alvarado‐Ramírez E. Microbiota fúngica nasal en sujetos alérgicos y sanos. Rev Iberoam Micol. 2007;24(2):125‐130.
Hartmann JE, Albrich WC, Dmitrijeva M, Kahlert CR. The effects of corticosteroids on the respiratory microbiome: a systematic review. Front Med. 2021;8:588584.
Gupta A, Bhanushali S, Karyakarte R, et al. Mycobiome profiling of nasopharyngeal region of SARS‐CoV‐2 infected individuals. Microb Infect. 2023;25(3):105059.
Yamamoto S, Saito M, Tamura A, Prawisuda D, Mizutani T, Yotsuyanagi H. The human microbiome and COVID‐19: A systematic review. PLoS One. 2021;16(6):e0253293.
Clinical guidance for management of adult COVID‐19 patients. Ministry of Health and Family Welfare, Government of India. 2023. Accessed August 11, 2023. https://www.icmr.gov.in/pdf/covid/techdoc/COVID_Clinical_Management_19032023.pdf
Kõljalg U, Nilsson HR, Schigel D, et al. The taxon hypothesis paradigm‐on the unambiguous detection and communication of taxa. Microorganisms. 2020;8(12):1910. doi:10.3390/microorganisms8121910
Andersen KS, Kirkegaard RH, Karst SM, Albertsen M. ampvis2: an R package to analyse and visualise 16S rRNA amplicon data. bioRxiv. Preprint published online April 11, 2018. doi:10.1101/299537
Arora U, Priyadarshi M, Katiyar V, et al. Risk factors for coronavirus disease‐associated mucormycosis. J Infect. 2022;84(3):383‐390.
Sarda R, Swain S, Ray A, Wig N. COVID‐19 associated mucormycosis and evolving evidence. Q J Med. 2021;115(6):422.
Ray A, Goel A, Wig N. Corticosteroids for treating mild COVID‐19: opening the floodgates of therapeutic misadventure. Q J Med. 2021;114(8):541‐542.
Swain S, Ray A, Sarda R, et al. COVID‐19‐associated subacute invasive pulmonary aspergillosis. Mycoses. 2021;65(1):57‐64.
Ray A, Jain D, Goel A, et al. Clinico‐pathological features in fatal COVID‐19 infection: a preliminary experience of a tertiary care center in North India using postmortem minimally invasive tissue sampling. Expert Rev Respir Med. 2021;15(10):1367‐1375.
Swain S, Sharma K, Ray A, et al. Post‐COVID‐19‐invasive pulmonary mycosis. Libyan Int Med Univ J. 2022;07(01):007‐011.
Santacroce L, Charitos IA, Ballini A, et al. The human respiratory system and its microbiome at a glimpse. Biology. 2020;9(10):318.
Kong HH, Morris A. The emerging importance and challenges of the human mycobiome. Virulence. 2017;8(3):310‐312.
Alvarez Baumgartner M, Li C, Kuntz TM, et al. Differences of the nasal microbiome and mycobiome by clinical characteristics of COPD patients. Chronic Obstr Pulm Dis. 2022;9(3):309‐324.
Zhang I, Pletcher SD, Goldberg AN, Barker BM, Cope EK. Fungal microbiota in chronic airway inflammatory disease and emerging relationships with the host immune response. Front Microbiol. 2017;8:2477.
Zhang H, Ai JW, Yang W, et al. Metatranscriptomic characterization of coronavirus disease 2019 identified a host transcriptional classifier associated with immune signaling. Clin Infect Dis. 2021;73(3):376‐385.
Hoque MN, Rahman MS, Sarkar MMH, et al. Transcriptome analysis reveals increased abundance and diversity of opportunistic fungal pathogens in nasopharyngeal tract of COVID‐19 patients. PLoS One. 2023;18(1):e0278134.
Huang C, Ni Y, Du W, Shi G. Effect of inhaled corticosteroids on microbiome and microbial correlations in asthma over a 9‐month period. Clin Transl Sci. 2022;15(7):1723‐1736.
Seelbinder B, Chen J, Brunke S, et al. Antibiotics create a shift from mutualism to competition in human gut communities with a longer‐lasting impact on fungi than bacteria. Microbiome. 2020;8:133.
Delavy M, Burdet C, Sertour N, et al. A clinical study provides the first direct evidence that interindividual variations in fecal β‐lactamase activity affect the gut mycobiota dynamics in response to β‐lactam antibiotics. mBio. 2022;13(6):e02880‐22.
Cleland EJ, Bassiouni A, Boase S, Dowd S, Vreugde S, Wormald PJ. The fungal microbiome in chronic rhinosinusitis: richness, diversity, postoperative changes and patient outcomes. Int Forum Allergy Rhinol. 2014;4(4):259‐265.
Huang YW, Wang WH, Lan MY. Analysing sinonasal microbiota of fungal rhinosinusitis by next‐generation sequencing. Clin Otolaryngol. 2023;48(2):313‐320.
Yuan H, Liu Z, Dong J, et al. The fungal microbiome of the upper airway is associated with future loss of asthma control and exacerbation among children with asthma. Chest. 2023;164(2):302‐313.
Romani L. Immunity to fungal infections. Nat Rev Immunol. 2011;11(4):275‐288.